290 related articles for article (PubMed ID: 21606974)
1. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.
Chey WD; Camilleri M; Chang L; Rikner L; Graffner H
Am J Gastroenterol; 2011 Oct; 106(10):1803-12. PubMed ID: 21606974
[TBL] [Abstract][Full Text] [Related]
2. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.
Wong BS; Camilleri M; McKinzie S; Burton D; Graffner H; Zinsmeister AR
Am J Gastroenterol; 2011 Dec; 106(12):2154-64. PubMed ID: 21876564
[TBL] [Abstract][Full Text] [Related]
3. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
Nakajima A; Seki M; Taniguchi S
J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Schoenfeld P; Lacy BE; Chey WD; Lembo AJ; Kurtz CB; Reasner DS; Bochenek W; Tripp K; Currie MG; Fox SM; Blakesley RE; OʼDea CR; Omniewski ND; Hall ML
Am J Gastroenterol; 2018 Jan; 113(1):105-114. PubMed ID: 29091082
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of linaclotide for patients with chronic constipation.
Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
[TBL] [Abstract][Full Text] [Related]
8. Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial.
Barish C; Dorn S; Fogel RP; Patel R; Rosenberg J
Dig Dis Sci; 2021 Feb; 66(2):537-540. PubMed ID: 32185662
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.
Miner PB; Koltun WD; Wiener GJ; De La Portilla M; Prieto B; Shailubhai K; Layton MB; Barrow L; Magnus L; Griffin PH
Am J Gastroenterol; 2017 Apr; 112(4):613-621. PubMed ID: 28169285
[TBL] [Abstract][Full Text] [Related]
10. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
[TBL] [Abstract][Full Text] [Related]
11. Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.
Lacy BE; Schey R; Shiff SJ; Lavins BJ; Fox SM; Jia XD; Blakesley RE; Hao X; Cronin JA; Currie MG; Kurtz CB; Johnston JM; Lembo AJ
PLoS One; 2015; 10(7):e0134349. PubMed ID: 26222318
[TBL] [Abstract][Full Text] [Related]
12. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
[TBL] [Abstract][Full Text] [Related]
13. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study.
Simrén M; Bajor A; Gillberg PG; Rudling M; Abrahamsson H
Aliment Pharmacol Ther; 2011 Jul; 34(1):41-50. PubMed ID: 21545606
[TBL] [Abstract][Full Text] [Related]
14. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis.
Nelson AD; Camilleri M; Chirapongsathorn S; Vijayvargiya P; Valentin N; Shin A; Erwin PJ; Wang Z; Murad MH
Gut; 2017 Sep; 66(9):1611-1622. PubMed ID: 27287486
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older.
Menees SB; Franklin H; Chey WD
Clin Ther; 2020 Jul; 42(7):1406-1414.e4. PubMed ID: 32660770
[TBL] [Abstract][Full Text] [Related]
17. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
Jamal MM; Adams AB; Jansen JP; Webster LR
Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
[TBL] [Abstract][Full Text] [Related]
19. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial.
Fukudo S; Endo Y; Hongo M; Nakajima A; Abe T; Kobayashi H; Nakata T; Nakajima T; Sameshima K; Kaku K;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):603-613. PubMed ID: 30056028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
